Mathematical Model of a Personalized Neoantigen Cancer Vaccine and the Human Immune System: Evaluation of Efficacy

Marisabel Rodriguez Messan¹, Osman N. Yogurtcu¹, Joseph R. McGill², Ujwani Nukala¹, Zuben E. Sauna², Hong Yang^{1*}

Appendix. Mathematical details, parameter estimation, and additional results

A. Brief mathematical analysis

Briefly, we present routinely used mathematical analysis to show that the system is positively invariant, that is, the solutions can never be negative. Dynamical systems theory states that if we start in a positively invariant subset of the state space from which the dynamics of the ODE are under consideration, then we are guaranteed to stay within the set no matter how long $(t \to \infty)$ we follow the dynamics of the ODE system.

Theorem 1. Assume all model parameters in Table A7 are positive. The system (1)-(15) is positive invariant in \mathbb{R}^{14}_+ .

Proof. We want to show that, if initial conditions of the state variables in our model are greater than 0, meaning, p(0) > 0, $A_d(0) > 0$, $D_I(0) > 0$, $D_M(0) > 0$, $p^E(0) > 0$, $M^E(0) > 0$, $pM^E(0) > 0$, M(0) > 0, $N_{CD4}(0) > 0$, $N_{CD8}(0) > 0$, $A_{CD4}(0) > 0$, $A_{CD8}(0) > 0$, and T(0) > 0, then for all t > 0, solutions to each of the state variables stay in the positive quadrant, meaning, p(t) > 0, $A_d(t) > 0$, $D_I(t) > 0$, $D_M(t) > 0$, $p^E(t) > 0$, $M^E(t) > 0$, $pM^E(t) > 0$, M(t) > 0, $N_{CD4}(t) > 0$, $N_{CD8}(t) > 0$, $A_{CD8}(t) > 0$, $M^E(t) > 0$, $M^E(t) > 0$, M(t) > 0, $N_{CD4}(t) > 0$, $N_{CD8}(t) > 0$, $A_{CD8}(t) > 0$, $A_{CD8}(t) > 0$, and T(t) > 0.

Thus, for any $p \ge 0$, $A_d \ge 0$, $D_I \ge 0$, $D_M \ge 0$, $p^E \ge 0$, $M^E \ge 0$, $pM^E \ge 0$, $pM \ge 0$, $M \ge 0$, $N_{CD4} \ge 0$, $N_{CD8} \ge 0$, $A_{CD4} \ge 0$, $A_{CD8} \ge 0$, and $T \ge 0$, whe have that

$$\begin{aligned} p'\Big|_{p=0} &= Dose_p \ge 0, \qquad A'_d\Big|_{A_d=0} = Dose_a \ge 0, \qquad D'_I\Big|_{D_I=0} = 0, \\ D'_M\Big|_{D_M=0} &= \frac{r_D A_d}{K_a + A_d} D_I \ge 0, \qquad N'_{CD4}\Big|_{N_{CD4}=0} = 0, \qquad N'_{CD8}\Big|_{N_{CD8}=0} = 0, \qquad T'\Big|_{T=0} = 0, \\ A'_{CD4}\Big|_{A_{CD4}=0} &= \sigma_{Nh} F_{P1} N_{CD4} \Phi_1 \ge 0, \qquad A'_{CD8}\Big|_{A_{CD8}=0} = \sigma_{Nc} F_{P2} N_{CD8} \Phi_3 \ge 0, \\ p^{E'}\Big|_{p^E=0} &= \alpha_p p \frac{V_E}{V_{sc}} \ge 0, \qquad M^{E'}\Big|_{M^E=0} = k_{\rm in} M \ge 0, \qquad p M^{E'}\Big|_{pM^E=0} = k_{\rm on} \cdot p^E \frac{M^E}{V_E} \ge 0 \\ pM'\Big|_{pM=0} &= k_{\rm ext} \cdot p M^E \ge 0, \qquad M'\Big|_{M=0} = k_{\rm off} \cdot p M \ge 0. \end{aligned}$$

This implies that due to the continuity of the system, it is impossible for any of these state variable solutions to drop below 0. \Box

B. Parameter Estimation

B.1. Estimating peptide concentration in a vaccine from amino acid sequences

We extracted the amino acid sequence of the peptides used for each patient's personalized vaccine used in the melanoma study [1] from their supplementary material. First, using all amino acid sequences of peptides in each vaccine, we calculated the protein molecular weight (KDa) by using the online tool *The Sequence Manipulation Suite: Protein Molecular Weight* [2]. Then, in [1], it was stated that each peptide had a weight of 0.3 mg. We used the online tool [3] to covert the weight concentration to pmol. In Table A1, we lay out each of the components necessary to calculate the peptide concentration, $Dose_p$ in pmol for input in our model.

Patient	No. of peptides	$egin{array}{c} { m Weight} \ { m (mg)} \end{array}$	Protein molecular weight (kDa)	$\begin{array}{c} \mathbf{Amount} \\ \mathbf{(pmol)} \end{array}$
1	13	3.9	32.68	119,340
2	17	5.1	42.49	120,030
3	14	4.2	38.33	$109,\!570$
4	14	4.2	36.03	116,570
5	20	6	54.12	110,860
6	20	6	53.66	111,820

Table A1. Peptide dose conversion from mg to pmol by patient with melanoma in [1].

B.2. Dendritic cells

Carrying capacity, K_{DC} . To estimate the carrying capacity of immature dendritic cells in the total volume of the subcutaneous tissue injection site, we used the total number of dendritic cells in Figure 4A of [4]. Since this article shows the total number of DCs by gender, we use the total number of DCs in females (approx. 27 number of cells/ μ L) as the lower bound of our range and we use the total number of DCs in males (approx. 35 number of cells/ μ L) as the upper bound. Estimating the number of DCs cells per volume we obtain:

27 to 35
$$\frac{\text{cells}}{\mu \text{L}} \cdot \frac{\mu \text{L}}{1 \times 10^{-6} \text{ L}} = 27 \text{ to } 35 \times 10^{6} \frac{\text{cells}}{\text{L}}$$

Now, to estimate the number of cells at the injection site, we multiply by the total volume of the subcutaneous tissue (V_{sc}) :

27 to
$$35 \times 10^6 \frac{\text{cells}}{\text{L}} \times 0.7676 \text{ L} = 2.07252 \text{ to } 2.6866 \times 10^7 \text{ cells}.$$

Thus, we choose 2.5×10^7 as the carrying capacity of immature dendritic cells.

Immature DCs maturation rate function: Half-maximum adjuvant effect constant, K_a , and maximum differentiation rate, r_D . To estimate parameters r_D and K_a , we fitted the analytical solution (see Eq. (1) below) of the second term in the equation of our model, $D'_I(t)$, representing the maturation rate of immature DCs to data from Figure 6A in [5] using Mathematica 12.0 [6] by looking for the best fit. The data from Figure 6A in [5] was extracted

using WebPlotDigitizer [7]. Figure 6A in [5], shows how DCs mature as a function of poly(I:C) adjuvant. In this figure, authors use CD83 since it is known that these are activation markers for antigen presenting cells [8]. We re-scaled %CD83⁺ cells to proportion of matured DCs in the y-axis and microgram per milliliter to milligram per liter in the x-axis of Figure 6A resulting in Figure 1 (see below).

Using separation of variables method, we find the analytical solution required to estimate r_D and K_a ,

$$\frac{dD_I(t)}{dt} = -\frac{r_D A_d}{K_a + A_d} D_I(t)$$
$$\frac{1}{D_I(t)} dD_I(t) = -\frac{r_D A_d}{K_a + A_d} dt$$

and integrate such that for all $t \in [0, T)$,

$$\int_{D_I(0)}^{D_I(T)} \left(\frac{1}{D_I(t)}\right) dD_I(t) = \int_0^T -\frac{r_D A_d}{K_a + A_d} dt$$
$$\ln(D_I(T)) - \ln(D_I(0)) = -\frac{r_D A_d}{K_a + A_d} T$$
$$D_I(T) = D_I(0) \exp\left(-\frac{r_D A_d}{K_a + A_d} T\right)$$

Now, assuming $D_M(0) = 0$ and $D_M(T) = D_I(0) - D_I(T)$ such that $\frac{D_M(T)}{D_I(0)} + \frac{D_I(T)}{D_I(0)} = 1$ (i.e., proportion of immature and mature DCs at time T equals to 1), then

$$\frac{D_M(T)}{D_I(0)} = 1 - \exp\left(-\frac{r_D A_d}{K_a + A_d}T\right)$$

According to the experiments done in [5], the cells were cultured for 24 hours before taking measurements of maturation. Hence, we set T = 1 (1 day) and the function to be fitted is:

$$f(x) = 1 - \exp\left(-\frac{r_D x}{K_a + x}\right) \tag{1}$$



Figure 1. Estimation of parameters r_D and K_a . Blue line represents the function: $f(x) = 1 - \exp\left(-\frac{r_D x}{K_a + x}\right)$, with $r_D = 3$ and $K_a = 10$, fitted to data extracted from Figure 6A in [5].

B.3. Estimation of parameters corresponding to the model equations that represent naïve T-cell populations

Initial counts of naïve T-cells, $N_{CD4}(0)$ and $N_{CD8}(0)$. In Ott et al. [1], eligible patients needed to have a lymphocyte count of at least 800 cells per microliter. We use these number as a baseline to estimate naïve CD4⁺ and CD8⁺ T-cell counts at t = 0 in our simulations. The average adult weighting 58 to 80 kilograms has about 4.5-5.7 L of blood. On average, using standard methods such as Ficoll-Paque density gradient centrifugation for PBMC yields $0.5-2\times10^9$ cells/L of blood [9]. We assume that patients have an average of 5 L of blood. This will give us 4×10^9 lymphocytes.

In Bittersohl et al. [9], authors provide percentages of different cells types which compose the PBMCs in a healthy adult human as shown in Table 9.1 of [9](see Table A2 below). From this table, we obtain that 70% of PBMCs are lymphocytes for which 60 out of 70 percent (about 86% of total lymphocytes) are T-cells and 10 out of the 70 percent (about 14% of total lymphocytes) are B-cells. Moreover, out the 86%, 70% are CD4⁺ and 30% are CD8⁺. With these percentages, we conclude that each patient will start with 2.408×10^9 naïve CD4⁺ T-cells and 1.032×10^9 CD8⁺ T-cells. This cell count represents a 2.34 CD4 to CD8 ratio of naïve T-cells.

Carrying capacities (K_{DC4} and K_{DC8}) for naïve CD4⁺ and CD8⁺ T-cells. In order to have a one-to-one comparison of T-cell count from extracted data and simulation, we use the previously estimated quantity of 1.42857×10^{12} PBMCs and Table A2 to estimate the CD4⁺ and CD8⁺ T-cells carrying capacities for our model. Thus, we conclude that T-cells = 8.57143×10^{11} (60% of PBMCs), then CD4⁺ T-cells = 6×10^{11} cells (70% of T-cells) and CD8⁺ T-cells = 2.57143×10^{11} cells (30% of T-cells).

B.4. IFN- γ ELISPOT of PBMCs data extraction

In Ott el al. Figure 2b [1], authors provided longitudinal plots to *ex-vivo* assay responses to peptide pools for each patient in the trial. These data points were reported by using IFN- γ

ELISPOT assay. This method allows the quantification of the number of CD4⁺ or CD8⁺ T-cells which secrete IFN- γ in response to a stimulation with a specific antigen or peptide [10,11]. Moreover, each spot within an ELISPOT well is the mark of a single cell that has released a relatively high amount of cytokines, in other words, the number of spots is a direct measure of the frequency of cytokine-producing T-cells [10]. Thus, we can say that the number of spots to number of cells is a one-to-one conversion. Given that each data point is in spot-forming cells per 10⁶ PBMCs, we first estimated the average number of PBMCs in a human. According to [12], a human has about 10¹² lymphocytes. Using Table A2, we estimate there are 1.42857 × 10¹² PBMCs.

Table A2.	Table	9.1	from	[9]
-----------	-------	-----	------	-----

Cell Type	%
T-cells $(CD3^+)$	60
Helper T-cells ($CD3^+$, $CD4^+$)	70 of T-cells
Cytotoxic T-cells $(CD3^+, CD8^+)$	30 of T-cells
B cells $(CD22^+)$	10
Monocytes/macrophages ($CD14^+$)	15
Natural killer (NK) cells (CD56 ⁺)/CD16 ⁺	15

To extract data from plots and images, we used WebPlotDigitizer [7]. Using R Studio [13], we plotted the extracted data (see Figure 2a) by patient. Each patient's frame contains the data of the four pools (Pool A - Pool D) which make up one vaccine dose and a baseline data (mock). Figure 2a is plotted in the form of cell counts by multiplying each extracted data point by 1.42857×10^6 . Then, in order to plot the total cell count of *ex-vivo* assay responses to peptides vaccine for each patient, we summed the data points of Pool A to Pool D at each time point and subtracted the Mock data resulting in Figure 2b.



Figure 2. Data transformation from *ex-vivo* IFN- γ ELISPOT responses for PBMCs in [1] to cell count. (a) Cell count of T-cell response of each pool in a vaccine by patient. (b) Total cell count T-cell response of each patient's vaccine with melanoma.

Activated CD4⁺ and CD8⁺ T-cell initial counts, $A_{CD4}(0)$ and $A_{CD8}(0)$. The first data point at day 0 for each patient in Figure 2b, was assigned to each patient's initial condition $A_{CD4}(0)$ and $A_{CD8}(0)$. Given that these data only tell us the T-cell count without making distinction between cell types, we assume that T-cell counts on day 0 are distributed as 70% activated CD4⁺ T-cells and 30% activated CD8⁺ T-cells. See Table A3 for details.

Patient	T-cell count on day 0	$A_{CD4}(0) \ (70\%)$	$A_{CD8}(0) \ (30\%)$
1	2.95×10^8	2.06×10^8	8.85×10^7
2	3.08×10^8	2.15×10^8	9.24×10^7
3	1.32×10^8	9.25×10^7	3.96×10^7
4	1.66×10^8	1.16×10^8	4.99×10^7
5	1.51×10^8	1.05×10^8	4.52×10^7
6	5.62×10^7	3.93×10^7	1.68×10^7

Table A3. Patient-specific initial counts for activated CD4⁺ and CD8⁺ T-cells (estimated from data in [1])

B.5. Parameters corresponding to the equation describing tumor cell population

Estimating maximum cancer growth rate, r. In Liu et al. [14], authors studied the rate of growth in melanomas, finding that one third of the melanomas grew at least 0.5 mm per month. The median monthly growth rate for nodular melanomas was 0.49 mm in diameter, superficial

spreading melanomas at 0.12 mm in diameter, and lentigo melanomas at 0.13 mm/month [14]. The patients sample for our simulations in [1] were diagnosed at different stages of melanoma cancer (see Table A5). Four of the patients who did not have recurrence after vaccine initiation had nodular melanomas (i.e., the tumor has spread to nearby lymph nodes [15]). However, all patients before initiating vaccine treatment, underwent surgery, thus, we assumed the growth rate of any residual after surgery is 0.15 mm/month in diameter. That is, we are assuming the best case scenario for these patients, regardless their initial tumor stage diagnosis.

To determine the number of cancer cells of a tumor in a spherical shape, we considered that each cell is about 20 μ m in diameter and a 1-mm cancer has about 100 thousand cells [16]. Therefore, to directly calculate the cell count in a tumor of diameter d, we used the formula of the volume of a sphere modified to incorporate a 25.95% of void volume [17], and multiply by 1×10^5 cells:

Total cell count in a spherical tumor:
$$T_c(d) = \frac{4\pi}{3} \left(\frac{d}{2}\right)^3 (0.7405) \cdot \frac{10^6 \text{ cells}}{\text{mm}^3},$$
 (2)

where d is the diameter in millimeters (mm).

The tumor growth rate is then calculated as follows:

1. Diameter per day:

$$\frac{0.15 \text{ mm}}{30 \text{ days}} = \frac{0.005 \text{mm}}{\text{day}}$$

2. Tumor volume (void volume removed) per day:

$$\frac{4\pi}{3} \left(\frac{0.004 \text{ mm}}{2}\right)^3 (0.7405) = 4.84 \times 10^{-8} \text{ mm}^3/\text{day}$$

3. Total tumor cell count per day:

$$4.84 \times 10^{-8} \text{ mm}^3/\text{day} \cdot 10^5 = 0.004 \text{ cells/day}$$

Estimating initial tumor cell count, T(0), by patient. To estimate the initial tumor cell count on day 0 (t = 0), we used the information provided for each of the patients in the 'Extended Data Table 1: Characteristics of patients' along with the clinical event timeline from surgery until time of data cut off in 'Figure 1', both in [1]. Then, following the guidelines from the American Cancer Society [15] and Melanoma Research Alliance [18] for melanoma skin cancer staging and using nodal staging and metastasis information on [19] and [20], respectively, we made the following assumptions which are then summarized in Table A4:

- (a) Given the tumor diameter ranges in [18] for each of the tumor thickness (**T**) in column 2 of Table A4, we make a definitive assumption for the tumor diameter.
- (b) According to [19], lymph nodes are considered malignant if they measure more than 1 cm in the short axis diameter. Though, the size threshold varies with anatomic site and underlying tumour type. For example, in rectal cancer lymph nodes are considered pathological when they measure more than 5 mm. Hence we assigned (column 5 of Table A4) the number of tumor-involved nodes according to the code (N).

(c) If a patient has metastasis (M), then in [20] it was stated that lung metastasis ranges between 3-7 cm. Hence, we assumed that patients with metastasis will have three 5-cm in diameter lung metastasis (column 7).

Tumor Stage	Tumor thickness at primary site	Assumption: size before surgery	Lymph nodes involvement	Assumption: no. of 5 mm tumor-involve nodes	Metastasis	Size: 3-7 cm
IIIC, IV	$\mathrm{T2} > 1\text{-}2~\mathrm{mm}$	$2 \mathrm{~mm}$	N0 (no regional metastasis)	0	M0	0
	T3 > 2-4 mm	$4 \mathrm{mm}$	N2 (2-3)	3	M1b	5cm (lung)
	T4 > 4 mm	$5 \mathrm{mm}$	N3 (4 or more)	5		John (lung)

Table A4. Definition of tumor diameter according to the American Joint Committee on Cancer (AJCC) TNM system [19].

As an example, we will walk you through the calculation to obtain the tumor cell count of Patient 2 at the beginning of cancer treatment (column 6 in Table A5):

• Patient 2 in [1] was diagnosed with T4N0M1b. Using Table A4, we conclude that T4 corresponds to a tumor diameter of 5 mm; N0 means there are no tumor-involved nodes; M1b corresponds to one 50-mm lung metastasis. Then using equation (2), we compute the tumor cell count for a tumor diameter of 5 mm, adding three times the tumor cell count for a tumor diameter,

$$T_c(5) + 3T_c(50).$$

Then, the tumor cell count after surgery is considered to be 5% of the tumor size before surgery. Thus, we multiply column 3 by 0.05. Lastly, we use the equation for tumor cells (Eq. (15) in the main text) without the second term which represents the intervention of the immune system. This means, we assume the tumor cells continue to grow without any mediation from the immune system.

$$\frac{dT}{d\tau} = 0.004 \left(1 - \frac{T(\tau)}{1.45 \times 10^{10}} \right) T(\tau)$$
(3)

In the equation above, we use 0.004 as the maximum growth rate estimated previously and 1.45×10^{10} as the tumor carrying capacity since this is the largest tumor cell count before surgery among patients (see column 2 in Table A5).

Patient	Stage by tumor thickness	Tumor cell count BEFORE surgery	Tumor cell count AFTER surgery (5%)	Time lag (days)	Tumor cell count at the beginning of treatment
1	T3 (N3M0)	1.702×10^7	$851\ 056$	120	1.375×10^6
2	T4 (N0M1b)	1.454×10^{10}	7.272×10^8	120	1.139×10^9
3	T3 (N2M0)	1.217×10^7	608 728	165	1.177×10^6
4	T4 (N2M0)	1.453×10^7	726 984	180	1.493×10^6
5	T2 (N2M0)	$1.0 imes 10^7$	$500\ 165$	135	858 265
6	T2 (N0M1b)	1.454×10^{10}	7.27×10^8	105	1.078×10^9

Table A5. Estimation of initial tumor cell count by patient at the beginning of vaccine treatment. Third column is estimated using Table A. Fourth column is estimated using equation (2). Fifth column is the time lag between surgery and initiation of cancer vaccine treatment. Sixth column is estimated using equation (3).

B.6. On-rate for T-epitope-MHCII binding, $k_{on,2}$

In [21], it is described that the maximum on-rate constant for binding is approximately 10^5 to 10^6 M⁻¹s⁻¹, i.e.,

$$\frac{(10^5 \text{ to } 10^6)}{M \cdot s} \cdot \frac{10^{-12}M}{pM} \cdot \frac{86400s}{day} = (8.64 \times 10^{-3} \text{ to } 8.64 \times 10^{-2}) \text{ pM}^{-1} \cdot \text{s}^{-1}$$

B.7. Detailed methodology for sensitivity analysis

We chose N = 500 as the number of LHS/PRC simulations. According to Marino et al., N should be at least K + 1, where K equals the number of uncertain model parameters (K = 12 in our study). As N increases, PRCC becomes more reliable, and statistical power for PRCC significance increases. Following the approach and algorithm described in [22], we constructed an LHS matrix of size N by K (N: no. of rows; K: no. of columns). Hence, each row corresponds to one simulation and contains a randomly selected and equally distributed value for each of the uncertain parameters of interest. Each of these rows in the LHS matrix is then used to calculate each of the outcome variables of interest producing N observations that are then used to assess the sensitivity of the outcome variables to the uncertainty in the input parameters. Next, we calculate the PRCC value for each outcome variable at specific time-points of interest (t = 25, 112, 147) following the approach of [22]. Sensitivity analysis simulations were performed in Mathematica, Version 12.0 [6].

Statistical significance of PRCC values were determined using Student's t-test to calculate the p-values of each computed PRCC values to evaluate if a PRCC is significantly different from zero and if two PRCCs are significantly different from each other. On each PRCC figure, we marked their statistical significance at different levels: at 0.05 level (*); at 0.01 level (**); at 0.001 level (***).

Below, are additional PRCC values corresponding to the patients not shown in the main text



for the corresponding outcome variables of interest.

Figure 3. Activated $CD4^+$ T-cell population sensitivity. PRCC values for the estimated parameters using the activated $CD4^+$ T cell population as the output of interest and patient-specific input parameters (vaccine peptides, HLA alleles, binding affinities). *, **, *** indicate statistical significance at 0.05, 0.01, and 0.001 level, respectively.



Figure 4. Activated CD8⁺ T-cell population sensitivity. PRCC values for the estimated parameters using the activated CD8⁺ T cell population as the output of interest and patient-specific input parameters (vaccine peptides, HLA alleles, binding affinities). *, **, *** indicate statistical significance at 0.05, 0.01, and 0.001 level, respectively.



Figure 5. Tumor cell population sensitivity. PRCC values for the estimated parameters using the Tumor cell population as the output of interest and patient-specific input parameters (vaccine peptides, HLA alleles, binding affinities). *, **, *** indicate statistical significance at 0.05, 0.01, and 0.001 level, respectively.

B.8. Methods for the 'Application' section

Using all patient-specific parameters (Table 2 and parameters obtained from [1]), we created six different patient profiles, and varied their initial tumor cell counts, which are assumed to be contained in a spherical shaped tumor with diameter d (see Table A6). To create a wide range of initial tumor cell counts corresponding to different tumor sizes (sample size: 2000), we used the LHS technique to get a uniform and equal distribution of tumor cell counts ranging from 30,000 to 2×10^{10} cells. Notice that this set of different initial conditions implicitly correspond to a total number of cells x number of days (or months) after having resection surgery. Keep in mind that there may be at least 5% tumor residue and may continue to grow post-surgery. Therefore, the estimated tumor cell count (or diameter) in Table A6 is the tumor cell count at day 0 of vaccine treatment.

Tumor cell count range	Diameter $d \pmod{m}$
$(3 \times 10^4, 5 \times 10^4]$	≤ 1
$(5 \times 10^4, 5 \times 10^5]$	(1, 2.4]
$(5 \times 10^5, \ 1 \times 10^7]$	(2.4, 6.4]
$(1 \times 10^7, 5 \times 10^8]$	(6.4, 23.45]
$(5 \times 10^8, \ 2 \times 10^{10}]$	(23.45, 89.2]

Table A6. Tumor cell count in a spherical shaped tumor with diameter d.

	Parameter	Definition	Value/Range	Value Used	Units
	$Dose_p$	Peptide concentration at each dose	varies	patient-specific \blacklozenge	pmol
e	$Dose_a$	Adjuvant concentration at each dose	$500 \ [1, 23]$	$\mathrm{mg/L}$	
accin	α_p	Internalization rate of peptides by DCs		0.28 [24]	day^{-1}
Š	$lpha_d$	Internalization rate of adjuvant by DCs		0.2 ★	day^{-1}
	V_{sc}	Volume of injections site	-	$4 \times (0.1919)$ [25]	L
	Λ	Maximum growth rate		3.75 ★	day^{-1}
)C)	δ_M	Death rate of mature DCs	(0.23, 0.54) [26]	0.11	day^{-1}
lls (I	r_D	Maximum differentiation rate		3 ♦	day^{-1}
ic ce	K_a	Half-maximum adjuvant effect constant		10 ♦	-
Dendrit	K_{DC}	Carrying capacity	$(2.07, 2.68) \times 10^7$	$2.5 imes 10^7$	cells
	V_E	Volume of endosomes in a DC	$(0.16, 1.35) \times 10^{-14}$ [27]	1×10^{-14}	L
	N_A	Avogadro's constant	-	6.02×10^{23}	mol^{-1}
	α_p^E	Endosomal internalization rate of peptides	[10.8, 144] $[27]$	70	day^{-1}
ation	β_p	Degradation rate of peptides	14.4-21.6 [28]	14.4	day^{-1}
oresent	$k_{\mathrm{OII},1}$	On rate for T-epitope-MHCI binding with allele j		1.8144×10^{-2} [29]	$pM^{-1} \cdot day^{-1}$
g and I	$k_{{\rm off},j}$	Off rate for T-epitope-MHCI binding with allele j	Neoantigen specific (based on $K_{D,j}^{\text{eff}}$)	$k_{\text{OD},1} \cdot K_{D,j}^{\text{eff}}$	day^{-1}
ocessin	$k_{\mathrm{ON},2}$	On rate for T-epitope-MHCII binding with allele \boldsymbol{k}	$\begin{array}{c} [0.43, 4.3] \times 10^{-2} \\ [27, 30] \end{array}$	$8.64\times10^{-3}~\blacklozenge$	$pM^{-1} \cdot day^{-1}$
gen pro	$k_{{\rm off},k}$	Off rate for T-epitope-MHCII binding with allele k	Neoantigen specific (based on $K_{D,k}^{\text{eff}}$)	$k_{\text{OD},2} \cdot K_{D,k}^{\text{eff}}$	day^{-1}
Antiș	β_M	Degradation rate of endosomal free MHCI/II molecules	0.92-2.08 [27]	1.663 [27]	day^{-1}
	$k_{ m in}$	Recycling rate of free MHC molecules	10.8-14.4 [27, 28]	14.4 [27]	day^{-1}
	$k_{ m ext}$	Exocytosis rate of p-MHC complex	17.28-43.2 [27,28]	28.8 [27]	day^{-1}
	β_{pM}	Degradation rate of p-MHCI/II complex	≥ 0.1663 [27]	0.166~[27]	day^{-1}
				Continued	on next page

Table A7. Parameter values and definition. (\clubsuit estimated from literature; \blacklozenge estimated from data (clinical/experimental); \bigstar fitted to trial data)

	Parameter	Description	Value/Range	Value Used	Units	
	a_1	Number of tumor cells needed for half-maximal A_{CD4} proliferation		patient-specific \bigstar	cells	
	a_2	Number of tumor cells needed for half-maximal A_{CD8} proliferation		patient-specific \bigstar	cells	
	b_1	Max. growth rate of naïve $CD4^+$ T-cells		0.15 ★	day^{-1}	
	b_2	Max. growth rate of naïve $CD8^+$ T-cells		0.12 ★	day^{-1}	
	σ_{Nh}	Max. activation rate of naïve $CD4^+$ T-cells		1.5 [27, 31]	day^{-1}	
	σ_{Nc}	Max. activation rate of naïve $CD8^+$ T-cells		3 [31]	day^{-1}	
	K_{TC4}	Carrying capacity of $CD4^+$ T-cells		6×10^{11} ♣	cells	
	K_{TC8}	Carrying capacity of $CD8^+$ T-cells		$2.57 imes 10^{11}$ ♣	cells	
lls	F_{P1}	Frequency of antigen-specific $CD4^+$ T-cells		patient-specific \bigstar	-	
T-ce]	F_{P2}	Freq. of antigen-specific $CD8^+$ T-cells		patient-specific \bigstar	-	
	K_{pM_1}	Half-maximum effect of activation	400 [24,27]	400	-	
	K_{pM_2}	Half-maximum effect of activation	$400 \ [24, 27]$	400	-	
	c_1	${\rm CD4^+}$ T-cells recruitment/prolif. rate		patient-specific \bigstar	day^{-1}	
	c_2	$\rm CD8^+$ T-cells recruitment/prolif. rate		patient-specific \bigstar	day^{-1}	
	μ_1	Death rate of activated CD4+ T-cells	(0.031, 0.083) [32]	0.031	day^{-1}	
	μ_2	Death rate of activated $CD8^+$ T-cells	(0.022, 0.052) [32]	0.022	day^{-1}	
	μ_3	Death rate of naïve T-cells		0.0029 ★	day^{-1}	
	$ ho_1$	Proliferation rate for activated CD4 ⁺ T-cells	1.51 [31]	$_{\star}^{\mathrm{patient-specific}}$	day^{-1}	
	$ ho_2$	Proliferation rate for activated CD8 ⁺ T-cells	(2.5,3) [33]	patient-specific \bigstar	day^{-1}	
	r	Maximum growth rate	tumor-type dependent	0.004 ♣	day^{-1}	
	K_T	Carrying capacity of tumor		$1.45\times10^{10}~\bigstar$	cells	
or cells	d	Max. lysis rate by activated CD4 ⁺ and CD8 ⁺ T-cells	(0.01, 0.05) [34]	patient-specific \bigstar	day^{-1}	
Tume	λ	Dependence of lysis rate on the effector/target ratio constant	(0.1,0.4)	$_{\star}^{\mathrm{patient-specific}}$	-	
	s_1	Half-maximal effect of tumor cell lysis	(0,10)	patient-specific \bigstar	-	
	s_2	Half-maximal effect of tumor cell lysis	(0,10)	patient-specific \bigstar	-	
	Continued on next page					

Table A7 –	continued	from	previous	page
------------	-----------	------	----------	------

	Parameter	Description	Value/Range	Value Used	Units
	$A_d(0)$	Adjuvant concentration in a vaccine		500	$\mathrm{mg/L}$
	p(0)	Peptide amount in a vaccine		patient-specific \blacklozenge	pmol
	$D_I(0)$	Immature dendritic cells		1×10^7	cells
	$D_M(0)$	Mature dendritic cells		0	cells
	$p^E(0)$	Endosomal peptides		0	pmol
	$M_j^E(0)$	Endosomal MHC-I		$(1.6, 5.8) \times 10^{-7}$ [24, 27]	pmol
su	$M_k^E(0)$	Endosomal MHC-II		$(0.16, 8.3) \times 10^{-8}$ [24, 27]	pmol
Initial Condition	$pM_j^E(0)$	Endosomal p-MHCI complex		0	pmol
	$pM_k^E(0)$	Endosomal p-MHCII complex		0	pmol
	$pM_j(0)$	p-MHCI on DC membrane		0	pmol
	$pM_k(0)$	p-MHCII on DC membrane		0	pmol
	$M_j(0)$	Free MHC-I on DC membrane		0	pmol
	$M_k(0)$	Free MHC-II on DC membrane		0	pmol
	$N_{CD4}(0)$	Naïve CD4 $^+$ T cell count		$2.408\times10^9~\clubsuit$	cells
	$N_{CD8}(0)$	Naïve $CD8^+$ T cell count		1.032×10^9	cells
	$A_{CD4}(0)$	Activated CD4 ⁺ T cell count		patient-specific \blacklozenge	cells
	$A_{CD8}(0)$	Activated $CD8^+$ T cell count		patient-specific \blacklozenge	cells
	T(0)	Tumor cell count		patient-specific \blacklozenge	cells

Table A7 – continued from previous page

References

- Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–221. doi:10.1038/nature22991.
- 2. Stothard P. The sequence manipulation suite: JavaScript programs for analyzing and formatting protein and DNA sequences.; 2000. Available from: https://www.bioinformatics.org/sms/prot_mw.html.
- Classical and molecular biology; Available from: http://www.molbiol.ru/eng/scripts/01_04.html.
- Orsini G, Legitimo A, Failli A, Massei F, Biver P, Consolini R. Enumeration of human peripheral blood dendritic cells throughout the life. International immunology. 2012;24(6):347–356.
- 5. Walker J, Tough DF. Modification of TLR-induced activation of human dendritic cells by type I IFN: synergistic interaction with TLR4 but not TLR3 agonists. Eur J Immunol. 2006;36(7):1827–36. doi:10.1002/eji.200635854.
- 6. Inc WR. Mathematica, Version 12.1;. Available from: https://www.wolfram.com/mathematica.
- 7. Rohatgi A. Webplotdigitizer: Version 4.3; 2020. Available from: https://automeris.io/WebPlotDigitizer.
- Li Z, Ju X, Silveira PA, Abadir E, Hsu WH, Hart DNJ, et al. CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential. Frontiers in Immunology. 2019;10:1312. doi:10.3389/fimmu.2019.01312.
- 9. Bittersohl H, Steimer W. Intracellular concentrations of immunosuppressants. In: Personalized Immunosuppression in Transplantation. Elsevier; 2016. p. 199–226.
- 10. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clinical and diagnostic laboratory immunology. 2001;8(5):871–879.
- 11. Wykes MN, Renia L. ELISPOT as say to measure peptide-specific IFN- γ production. Bio-protocol. 2017;7 (11):e2302–e2302.
- 12. Perelson AS, Weisbuch G. Immunology for physicists. Reviews of modern physics. 1997;69(4):1219.
- 13. RStudio Team. RStudio: Integrated Development Environment for R; 2019. Available from: http://www.rstudio.com/.
- Liu W, Dowling JP, Murray WK, McArthur GA, Thompson JF, Wolfe R, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Archives of dermatology. 2006;142(12):1551–1558.

- 15. Society AC. Melanoma Skin Cancer Stages; 2019. Available from: https://www.cancer.org/cancer/melanoma-skin-cancer/ detection-diagnosis-staging/melanoma-skin-cancer-stages.html.
- 16. Seriesa AC, Narod S. Disappearing breast cancers. Current Oncology. 2012;19(2):59.
- 17. Agustin-Bunch F. How many cancer cells are in a tumor?;. Available from: https://drfarrahcancercenter.com/how-many-cancer-cells-are-in-a-tumor/.
- Alliance MR. Understanding Melanoma Staging; 2020. Available from: https://www.curemelanoma.org/about-melanoma/melanoma-staging/ understanding-melanoma-staging/.
- 19. Ganeshalingam S, Koh DM. Nodal staging. Cancer Imaging. 2009;9(1). doi:10.1102/1470-7330.2009.0017.
- 20. Shan Q, Fan Y, Guo J, Han X, Wang H, Wang Z. Relationship between tumor size and metastatic site in patients with stage IV non-small cell lung cancer: A large SEER-based study. PeerJ. 2019;7:e7822. doi:10.7717/peerj.7822.
- 21. Foote J, Eisen HN. Kinetic and affinity limits on antibodies produced during immune responses. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(5):1254.
- 22. Marino S, Hogue IB, Ray CJ, Kirschner DE. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biol. 2008;254(1):178–96. doi:10.1016/j.jtbi.2008.04.011.
- Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234–239. doi:10.1038/s41586-018-0792-9.
- 24. Chen X, Hickling T, Vicini P. A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1—theoretical model. CPT: pharmacometrics & systems pharmacology. 2014;3(9):1–9.
- 25. Tegenge MA, Mitkus RJ. A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines. Journal of pharmacokinetics and pharmacodynamics. 2013;40(5):545–556.
- 26. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell. 2001;106(3):263–266.
- Yogurtcu ON, Sauna ZE, McGill JR, Tegenge MA, Yang H. TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity. The AAPS journal. 2019;21(5):96.
- 28. Singer DF, Linderman JJ. The relationship between antigen concentration, antigen internalization, and antigenic complexes: modeling insights into antigen processing and presentation. The Journal of cell biology. 1990;111(1):55–68.

- Corr M, Slanetz A, Boyd L, Jelonek M, Khilko S, al Ramadi B, et al. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science. 1994;265(5174):946–949. doi:10.1126/science.8052850.
- Kasson PM, Rabinowitz JD, Schmitt L, Davis MM, McConnell HM. Kinetics of peptide binding to the class II MHC protein I- Ek. Biochemistry. 2000;39(5):1048–1058.
- Lee HY, Topham DJ, Park SY, Hollenbaugh J, Treanor J, Mosmann TR, et al. Simulation and prediction of the adaptive immune response to influenza A virus infection. Journal of virology. 2009;83(14):7151–7165.
- 32. Ribeiro RM, Mohri H, Ho DD, Perelson AS. In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted? Proceedings of the National Academy of Sciences. 2002;99(24):15572–15577.
- 33. De Boer RJ, Oprea M, Antia R, Murali-Krishna K, Ahmed R, Perelson AS. Recruitment times, proliferation, and apoptosis rates during the CD8+ T-cell response to lymphocytic choriomeningitis virus. Journal of virology. 2001;75(22):10663–10669.
- Rhodes A, Hillen T. A mathematical model for the immune-mediated theory of metastasis. Journal of theoretical biology. 2019;482:109999.